Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
Figure 4
Sensitivity analyses for the influence of individual studies on the summary OR for the association between trastuzumab administration and DFS (including the DCarboT arm of the BCIRG 006 trial).
The vertical midline indicates the overall OR and the lateral vertical lines indicate its 95% CI. Every hollow round indicates the pooled OR when the left study is omitted in this meta-analysis. The two ends of every dotted line represent the respective 95% CI.